The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer ...

Get the next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients ...

Norges Bank bought a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC.

Credit: fizkes via Shutterstock. On 7 April 2025 at the American Academy of Neurology (AAN) 2025 annual meeting held in San Diego, California, Axsome Therapeutics presented efficacy and safety data ...

7 analysts have shared their evaluations of Voyager Therapeutics VYGR during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise ...

Series A financing co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures Merida Biosciences, a biotechnology company pioneering a new class of precision therapeutics designed ...

Introduced in FY23, Lupin Digital Health marked the company’s foray into the fast-growing digital therapeutics space. Its Lyfe platform focuses on real-time monitoring of patients and offers ...

New York, New York--(Newsfile Corp. - April 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for ...

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for central nervous system (CNS) diseases. The deal gives Lilly an exclusive ...

The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions ...